Skip to main content

Advertisement

Log in

Dose specific effects of olanzapine in the treatment of alcohol dependence

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

It is well established that the rewarding effects of alcohol are modulated by the mesolimbic dopaminergic system. Olanzapine, a D2 dopamine antagonist, has been shown to reduce alcohol craving and consumption.

Objective

To clarify whether olanzapine has clinical utility in the treatment of alcohol dependence, a 12-week, double-blind, and randomized clinical trial was conducted.

Methods

One hundred twenty-nine treatment-seeking alcohol-dependent adults were randomly assigned to 12 weeks of olanzapine (5 vs. 2.5 mg) or placebo. Outcomes examined were average drinks per drinking day (DDD), proportion of drinking days (PDD) to total days in treatment, alcohol craving, and impaired control over alcohol use. Mixed models were used to examine medication effects during the course of treatment on specified outcomes.

Results

All of the analyses indicated a main effect for time, such that there were reductions in alcohol use and craving and an increase in control over alcohol use across treatment conditions. Dose-response analyses indicated that, in comparison to placebo, participants in the 5 mg group experienced reduced craving for alcohol and participants in the 2.5 mg group decreased in PDD and increased in their control over alcohol use. Better control over alcohol use remained significant 6 months post-treatment for the 2.5 mg group. Subjective experiences of the medication suggest that 2.5 and 5 mg were equally well tolerated.

Conclusions

Results provide some support for the notion that dosage is an important consideration in relation to effectiveness; however, the cost-benefit balance does not support the clinical utility of olanzapine in treating alcohol dependence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The primary investigator, Kent Hutchison, PhD, moved his lab from CU-Boulder to MRN-Albuquerque in 2007. The grant funding of this study was also moved.

References

  • Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28(1):5–12

    Article  CAS  PubMed  Google Scholar 

  • Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19(3):600–606

    Article  CAS  PubMed  Google Scholar 

  • Brunetti M, Di Tizio L, Dezi S, Pozzi G, Grandinetti P, Martinotti G (2012) Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci 16(10):1346–1354

    CAS  PubMed  Google Scholar 

  • Cohen, J., West, S., Aiken, L., & Cohen, P. (2002). Applied multiple regression/correlation analysis for the behavioral sciences: Lawrence Erlbaum Associates

  • Del Boca FK, Kranzler HR, Brown J, Korner PF (1996) Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 20(8):1412–1417

  • Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M, Casas M (2004) A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res 28(5):736–745

    Article  CAS  PubMed  Google Scholar 

  • Heather N, Tebbutt JS, Mattick RP, Zamir R (1993) Development of a scale for measuring impaired control over alcohol consumption: a preliminary report. J Stud Alcohol 54(6):700–709

    Article  CAS  PubMed  Google Scholar 

  • Heather N, Booth P, Luce A (1998) Impaired control scale: cross-validation and relationships with treatment outcome. Addiction 93(5):761–771

    Article  CAS  PubMed  Google Scholar 

  • Hutchison KE (2010) Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. Annu Rev Clin Psychol 6:577–589

    Article  PubMed  Google Scholar 

  • Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28(10):1882–1888

    Article  CAS  PubMed  Google Scholar 

  • Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31(6):1310–1317

    CAS  PubMed  Google Scholar 

  • Janiri L, Martinotti G, Di Nicola M (2007) Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J Clin Psychopharmacol 27(5):519–520

    Article  PubMed  Google Scholar 

  • Karoly HC, Harlaar N, Hutchison KE (2013) Substance use disorders: a theory-driven approach to the integration of genetics and neuroimaging. Ann N Y Acad Sci 1282:71–91

    Article  CAS  PubMed  Google Scholar 

  • Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry 74(7):e642–e654

    Article  PubMed  Google Scholar 

  • Koob GF (2013) Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder. Curr Top Behav Neurosci 13:3–30

    Article  PubMed Central  PubMed  Google Scholar 

  • Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ, Oncken C (2008) Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 32(4):573–579

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Stout R (2012) A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 36(3):406–416

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Marsh A, Smith L, Saunders B, Piek J (2002) The impaired control scale: confirmation of factor structure and psychometric properties for social drinkers and drinkers in alcohol treatment. Addiction 97(10):1339–1346

    Article  CAS  PubMed  Google Scholar 

  • Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L (2008) Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 23(5):417–424

    Article  CAS  PubMed  Google Scholar 

  • Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65(4):466–475

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ (2004) COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. DHHS Publication No. (NIH) 04–5289. Bethesda, MD: NIAAA

  • Ray LA, Heydari A, Zorick T (2010) Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev 29(5):568–575

    Article  PubMed  Google Scholar 

  • Schafer JL, Graham JW (2002) Missing data: our view of the state of the art. Psychol Methods 7(2):147–177

    Article  PubMed  Google Scholar 

  • Singer J (2002) Fitting individual growth models using SAS PROC MIXED. Modeling intra-individual variability with repeated measures data: methods and applications (pp. 135–170). Lawrence Erlbaum Associates, Mahwah

    Google Scholar 

  • Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91(3):199–209

  • Sobell L, Sobell M (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (eds) Measuring alcohol consumption: psychosocial and biochemical methods. Humana Press, Totowa, pp 41–72

    Chapter  Google Scholar 

  • Voronin K, Randall P, Myrick H, Anton R (2008) Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm—possible influence of self-control. Alcohol Clin Exp Res 32(11):1954–1961

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zempleni J, Galloway JR, McCormick DB (1996) Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 63:54–66

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rae A. Littlewood.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Littlewood, R.A., Claus, E.D., Arenella, P. et al. Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology 232, 1261–1268 (2015). https://doi.org/10.1007/s00213-014-3757-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3757-1

Keywords

Navigation